TY - JOUR
T1 - Inflamed and non-inflamed classes of HCC
T2 - A revised immunogenomic classification
AU - Montironi, Carla
AU - Castet, Florian
AU - Haber, Philipp K.
AU - Pinyol, Roser
AU - Martin, Miguel Torres
AU - Torrens, Laura
AU - Wang, Huan
AU - Puigvehi, Marc
AU - Maeda, Miho
AU - Leow, Wei Qiang
AU - Harrod, Elizabeth
AU - Taik, Patricia
AU - Chinburen, Jigjidsuren
AU - Taivanbaatar, Erdenebileg
AU - Chinbold, Enkhbold
AU - Arqués, Manel Solé
AU - Donovan, Michael
AU - Thung, Swan
AU - Neely, Jaclyn
AU - Mazzaferro, Vincenzo
AU - Anderson, Jeffrey
AU - Roayaie, Sasan
AU - Schwartz, Myron
AU - Villanueva, Augusto
AU - Friedman, Scott L.
AU - Uzilov, Andrew
AU - Sia, Daniela
AU - Llovet, Josep M.
N1 - Publisher Copyright:
© 2023 BMJ Publishing Group. All rights reserved.
PY - 2023
Y1 - 2023
N2 - Objective We previously reported a characterisation of the hepatocellular carcinoma (HCC) immune contexture and described an immune-specific class. We now aim to further delineate the immunogenomic classification of HCC to incorporate features that explain responses/resistance to immunotherapy. Design We performed RNA and whole-exome sequencing, T-cell receptor (TCR)-sequencing, multiplex immunofluorescence and immunohistochemistry in a novel cohort of 240 HCC patients and validated our results in other cohorts comprising 660 patients. Results Our integrative analysis led to define: (1) the inflamed class of HCC (37%), which includes the previously reported immune subclass (22%) and a new immune-like subclass (15%) with high interferon signalling, cytolytic activity, expression of immune-effector cytokines and a more diverse T-cell repertoire. A 20-gene signature was able to capture 90% of these tumours and is associated with response to immunotherapy. Proteins identified in liquid biopsies recapitulated the inflamed class with an area under the ROC curve (AUC) of 0.91; (2) The intermediate class, enriched in TP53 mutations (49% vs 29%, p=0.035), and chromosomal losses involving immune-related genes and; (3) the excluded class, enriched in CTNNB1 mutations (93% vs 27%, p0.001) and PTK2 overexpression due to gene amplification and promoter hypomethylation. CTNNB1 mutations outside the excluded class led to weak activation of the Wnt-catenin pathway or occurred in HCCs dominated by high interferon signalling and type I antigen presenting genes. Conclusion We have characterised the immunogenomic contexture of HCC and defined inflamed and non-inflamed tumours. Two distinct CTNNB1 patterns associated with a differential role in immune evasion are described. These features may help predict immune response in HCC.
AB - Objective We previously reported a characterisation of the hepatocellular carcinoma (HCC) immune contexture and described an immune-specific class. We now aim to further delineate the immunogenomic classification of HCC to incorporate features that explain responses/resistance to immunotherapy. Design We performed RNA and whole-exome sequencing, T-cell receptor (TCR)-sequencing, multiplex immunofluorescence and immunohistochemistry in a novel cohort of 240 HCC patients and validated our results in other cohorts comprising 660 patients. Results Our integrative analysis led to define: (1) the inflamed class of HCC (37%), which includes the previously reported immune subclass (22%) and a new immune-like subclass (15%) with high interferon signalling, cytolytic activity, expression of immune-effector cytokines and a more diverse T-cell repertoire. A 20-gene signature was able to capture 90% of these tumours and is associated with response to immunotherapy. Proteins identified in liquid biopsies recapitulated the inflamed class with an area under the ROC curve (AUC) of 0.91; (2) The intermediate class, enriched in TP53 mutations (49% vs 29%, p=0.035), and chromosomal losses involving immune-related genes and; (3) the excluded class, enriched in CTNNB1 mutations (93% vs 27%, p0.001) and PTK2 overexpression due to gene amplification and promoter hypomethylation. CTNNB1 mutations outside the excluded class led to weak activation of the Wnt-catenin pathway or occurred in HCCs dominated by high interferon signalling and type I antigen presenting genes. Conclusion We have characterised the immunogenomic contexture of HCC and defined inflamed and non-inflamed tumours. Two distinct CTNNB1 patterns associated with a differential role in immune evasion are described. These features may help predict immune response in HCC.
UR - http://www.scopus.com/inward/record.url?scp=85142200485&partnerID=8YFLogxK
U2 - 10.1136/gutjnl-2021-325918
DO - 10.1136/gutjnl-2021-325918
M3 - Article
C2 - 35197323
AN - SCOPUS:85142200485
SN - 0017-5749
VL - 72
SP - 129
EP - 140
JO - Gut
JF - Gut
IS - 1
ER -